bioMérieux in the news

bioMérieux launched its SPINCHIP point-of-care platform with a cardiac troponin I test, showing positive short-term stock movement despite a long-term decline, with its fair value currently assessed as slightly overvalued.

bioMérieux stock experienced a slight 0.43% decrease to 80.400• on the Paris stock exchange, despite a 4.15% gain over the last week, contrasting with a 29.72% drop over the past year.

Biomerieux's stock surged by 4.67% to 81.80 euros, surpassing a key resistance level and showing strong bullish momentum towards a 102.00 euros target.

BioMérieux's stock increased by 4.61% to 81.75    , breaking past a key resistance level while the company confirmed its 2026 financial outlook and launched a new emergency room diagnostic test.

bioMérieux's stock price increased significantly, breaking a key resistance level, while the company confirmed its annual financial outlook and launched a new diagnostic product.

bioMérieux's stock increased by over 2% and the company launched a new rapid troponin test while maintaining its 2026 financial outlook.

Ashish Gupta has rejoined bioMérieux as VP and GM for India and neighboring markets, bringing 24 years of IVD industry experience to lead market expansion and growth.

Ashish Gupta rejoined bioMérieux as Vice President & General Manager for India & Neighboring Markets, bringing over 20 years of diagnostics industry experience.

bioMérieux introduced SPINCHIP®, a new point-of-care immunoassay platform that quickly diagnoses heart attacks from a single blood drop, aiming to expand its presence in emergency care.

bioMérieux's stock rose 2.21% to  78.45, exceeding short-term averages and approaching a  79.70 resistance level, following the confirmation of its 2026 outlook and the launch of its Spinchip troponin test.

bioMérieux launched SPINCHIP®, a new point-of-care platform featuring a rapid, high-sensitivity cardiac troponin I test for quicker diagnosis of acute myocardial infarction in emergency departments.

Investment experts debated buying or selling shares of Biomérieux and CATL on a French business show.

bioMérieux's stock closed down 0.58% at 76.750   in Paris today.

bioMérieux's stock rose over 12% in a week, driven by the launch of Spinchip, despite mixed fundamental results from the first half of 2026.

bioMérieux has launched SPINCHIP, a new point-of-care platform, with the stock showing recent gains despite long-term underperformance and a slight undervaluation according to analysts.

bioMérieux's stock rose significantly over the past week, driven by the launch of its Spinchip platform, despite previous negative impacts from currency exchange and reduced respiratory panel sales.

bioMérieux has launched an ultrafast, compact diagnostic test for heart attacks, providing results in ten minutes from a finger-prick blood sample.

bioMérieux has launched Spinchip, a rapid point-of-care diagnostic platform with an initial test for hypersensitive cardiac troponin I, to accelerate the diagnosis of myocardial infarction in emergency settings.